Early Defect of Transforming Growth Factor β1 Formation in Huntington's Disease
Overview
Molecular Biology
Authors
Affiliations
A defective expression or activity of neurotrophic factors, such as brain- and glial-derived neurotrophic factors, contributes to neuronal damage in Huntington's disease (HD). Here, we focused on transforming growth factor-β (TGF-β(1) ), a pleiotropic cytokine with an established role in mechanisms of neuroprotection. Asymptomatic HD patients showed a reduction in TGF-β(1) levels in the peripheral blood, which was related to trinucleotide mutation length and glucose hypometabolism in the caudate nucleus. Immunohistochemical analysis in post-mortem brain tissues showed that TGF-β(1) was reduced in cortical neurons of asymptomatic and symptomatic HD patients. Both YAC128 and R6/2 HD mutant mice showed a reduced expression of TGF-β(1) in the cerebral cortex, localized in neurons, but not in astrocytes. We examined the pharmacological regulation of TGF-β(1) formation in asymptomatic R6/2 mice, where blood TGF-β(1) levels were also reduced. In these R6/2 mice, both the mGlu2/3 metabotropic glutamate receptor agonist, LY379268, and riluzole failed to increase TGF-β(1) formation in the cerebral cortex and corpus striatum, suggesting that a defect in the regulation of TGF-β(1) production is associated with HD. Accordingly, reduced TGF-β(1) mRNA and protein levels were found in cultured astrocytes transfected with mutated exon 1 of the human huntingtin gene, and in striatal knock-in cell lines expressing full-length huntingtin with an expanded glutamine repeat. Taken together, our data suggest that serum TGF-β(1) levels are potential biomarkers of HD development during the asymptomatic phase of the disease, and raise the possibility that strategies aimed at rescuing TGF-β(1) levels in the brain may influence the progression of HD.
Bedolla A, Wegman E, Weed M, Stevens M, Ware K, Paranjpe A Nat Commun. 2024; 15(1):5306.
PMID: 38906887 PMC: 11192737. DOI: 10.1038/s41467-024-49596-0.
Exploring potential developmental origins of common neurodegenerative disorders.
Catlin J, Schaner Tooley C Biochem Soc Trans. 2024; 52(3):1035-1044.
PMID: 38661189 PMC: 11440815. DOI: 10.1042/BST20230422.
Jin B, Fei G, Sang S, Zhong C Front Mol Neurosci. 2023; 16:1152279.
PMID: 37234685 PMC: 10205980. DOI: 10.3389/fnmol.2023.1152279.
Interleukin-6 as a marker of Huntington's disease progression: Systematic review and meta-analysis.
Eide S, Misztal M, Feng Z Brain Behav Immun Health. 2023; 30:100635.
PMID: 37215308 PMC: 10196779. DOI: 10.1016/j.bbih.2023.100635.
The updated development of blood-based biomarkers for Huntington's disease.
Zhang S, Cheng Y, Shang H J Neurol. 2023; 270(5):2483-2503.
PMID: 36692635 PMC: 9873222. DOI: 10.1007/s00415-023-11572-x.